Published in Psychiatry Res on July 18, 2013
Toward earlier identification and preventative intervention in schizophrenia: evidence from the London Child Health and Development Study. Soc Psychiatry Psychiatr Epidemiol (2015) 1.44
The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry (2014) 0.93
Approaching a network connectivity-driven classification of the psychosis continuum: a selective review and suggestions for future research. Front Hum Neurosci (2015) 0.82
Towards indicated prevention of psychosis: using probabilistic assessments of transition risk in psychosis prodrome. J Neural Transm (Vienna) (2014) 0.81
Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis. Neuropsychopharmacology (2014) 0.81
Current status specifiers for patients at clinical high risk for psychosis. Schizophr Res (2014) 0.77
Intensive Auditory Cognitive Training Improves Verbal Memory in Adolescents and Young Adults at Clinical High Risk for Psychosis. Schizophr Bull (2016) 0.77
The Role of Trauma and Stressful Life Events among Individuals at Clinical High Risk for Psychosis: A Review. Front Psychiatry (2017) 0.75
Early Detection of Psychosis: Recent Updates from Clinical High-Risk Research. Curr Behav Neurosci Rep (2015) 0.75
Brain development in adolescents at ultra-high risk for psychosis: Longitudinal changes related to resilience. Neuroimage Clin (2016) 0.75
Predicting early transition from sub-syndromal presentations to major mental disorders. BJPsych Open (2017) 0.75
Improving outcomes of first-episode psychosis: an overview. World Psychiatry (2017) 0.75
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (2008) 6.24
Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry (2012) 5.45
The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry (2013) 4.16
Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol (2007) 2.60
Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry (2012) 2.39
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07
Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol (2005) 1.96
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Regional gray matter volume abnormalities in the at risk mental state. Biol Psychiatry (2006) 1.81
Psychotic experiences in the general population: a twenty-year prospective community study. Schizophr Res (2007) 1.77
Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies. Schizophr Bull (2011) 1.72
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry (2009) 1.71
[Do psychiatric patients receive disability pension before adequate diagnostics and treatment? Evaluation of 101 psychiatric expertises done on behalf of Swiss Invalidity Insurance and the Psychiatric Outpatient Department Basel in 2002]. Psychiatr Prax (2005) 1.70
Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci Biobehav Rev (2007) 1.67
Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev (2012) 1.67
The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res (2006) 1.66
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology (2009) 1.62
The attenuated psychosis syndrome in DSM-5. Schizophr Res (2013) 1.61
Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One (2013) 1.59
The phenomenology and neurobiology of delusion formation during psychosis onset: Jaspers, Truman symptoms, and aberrant salience. Schizophr Bull (2013) 1.58
Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry (2009) 1.56
Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res (2010) 1.52
Duration of untreated psychosis and cognitive functioning. Schizophr Res (2013) 1.47
Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. Schizophr Res (2009) 1.43
Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res (2008) 1.43
Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry (2009) 1.40
Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol (2009) 1.40
Diffusion tensor imaging in the early phase of schizophrenia: what have we learned? J Psychiatr Res (2010) 1.32
A randomized, double-blind, placebo-controlled study of light therapy for antepartum depression. J Clin Psychiatry (2011) 1.32
Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum Brain Mapp (2009) 1.32
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol (2010) 1.31
Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. Arch Gen Psychiatry (2011) 1.30
Neural correlates of executive function and working memory in the 'at-risk mental state'. Br J Psychiatry (2009) 1.29
Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry (2008) 1.24
Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol Sci (2008) 1.24
Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int J Methods Psychiatr Res (2012) 1.21
Co-occurring mental and substance abuse disorders: a review on the potential predictors and clinical outcomes. Psychiatry Res (2010) 1.19
The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions. Schizophr Res (2006) 1.18
White matter alterations in early stages of schizophrenia: a systematic review of diffusion tensor imaging studies. J Neuroimaging (2013) 1.17
Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem (2013) 1.16
Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. Br J Psychiatry Suppl (2007) 1.16
Whither the attenuated psychosis syndrome? Schizophr Bull (2012) 1.12
Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol (2009) 1.12
Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: a meta-analysis of controlled magnetic resonance imaging studies. Curr Pharm Des (2012) 1.11
Brain connectivity abnormalities predating the onset of psychosis: correlation with the effect of medication. JAMA Psychiatry (2013) 1.11
Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull (2014) 1.10
Disability in people clinically at high risk of psychosis. Br J Psychiatry (2010) 1.10
Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk. Schizophr Res (2011) 1.10
Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry (2012) 1.07
Risperidone-induced leucopenia and neutropenia: a case report. Eur Psychiatry (2004) 1.07
Multifaceted impairments of impulsivity in cannabis users? Psychol Med (2013) 1.06
Domestic violence against women: Definitions, epidemiology, risk factors and consequences. Swiss Med Wkly (2010) 1.06
Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab (2007) 1.06
Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res (2012) 1.05
Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des (2012) 1.05
Potential reporting bias in fMRI studies of the brain. PLoS One (2013) 1.05
Reduced mismatch negativity predates the onset of psychosis. Schizophr Res (2011) 1.05
Third-generation neuroimaging in early schizophrenia: translating research evidence into clinical utility. Br J Psychiatry (2012) 1.03
Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. Schizophr Bull (2012) 1.03
Tracking cerebral white matter changes across the lifespan: insights from diffusion tensor imaging studies. J Neural Transm (Vienna) (2013) 1.02
White matter fibertracking in first-episode schizophrenia, schizoaffective patients and subjects at ultra-high risk of psychosis. Neuropsychobiology (2008) 1.02
Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res (2011) 1.02
Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. J Psychiatr Res (2009) 1.01
Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Can J Psychiatry (2010) 1.00
Neuropsychological deficits in individuals with an at risk mental state for psychosis - working memory as a potential trait marker. Schizophr Res (2007) 0.98
Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis. Schizophr Bull (2011) 0.97
Altered prefrontal and hippocampal function during verbal encoding and recognition in people with prodromal symptoms of psychosis. Schizophr Bull (2009) 0.97
Different duration of at-risk mental state associated with neurofunctional abnormalities. A multimodal imaging study. Hum Brain Mapp (2011) 0.97
Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review. World J Biol Psychiatry (2013) 0.96
Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study. Schizophr Bull (2011) 0.96
Is cannabis neurotoxic for the healthy brain? A meta-analytical review of structural brain alterations in non-psychotic users. Psychiatry Clin Neurosci (2013) 0.95
White matter abnormalities in adults with 22q11 deletion syndrome with and without schizophrenia. Schizophr Res (2011) 0.94
'Truman' signs and vulnerability to psychosis. Br J Psychiatry (2008) 0.93
Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr Res (2013) 0.93
Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. Aust N Z J Psychiatry (2010) 0.93
Affective temperamental profiles are associated with white matter hyperintensity and suicidal risk in patients with mood disorders. J Affect Disord (2010) 0.93
Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry (2013) 0.93
Mapping vulnerability to bipolar disorder: a systematic review and meta-analysis of neuroimaging studies. J Psychiatry Neurosci (2012) 0.92
Distinguishing prodromal from first-episode psychosis using neuroanatomical single-subject pattern recognition. Schizophr Bull (2012) 0.92
Insight in psychosis: relationship with neurocognition, social cognition and clinical symptoms depends on phase of illness. Schizophr Bull (2010) 0.92
AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. Eur J Nucl Med Mol Imaging (2008) 0.91